Gilead Sciences (NASDAQ:GILD)

payoff

5 US Companies Focused on Returning Capital to Shareholders

If the 2008 recession and stock market calamity taught one lesson to chief financial officers of major corporations, it was one of lowering leverage, issuing less new debt and taking ...
Read Full Story »
research

Short Sellers Increase Bets Against Biotech as Shares Continue to Rise

The short interest data are out for the February 13 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
Comfortable hospital bed

Top UBS Health Care Stocks to Buy for 2015 and Beyond

As the market surges higher, investors start to get a touch more concerned about where they allocate capital. One sector that is consistently ranked as an overweight from almost every ...
Read Full Story »
biotech

Analyst’s 4 Blue-Chip Biotech Stocks to Buy for the Rest of 2015

Since the beginning of the year, there has been a flood of biotech initial public offerings (IPOs) and secondaries, and the market has become so oversaturated that some of the ...
Read Full Story »
Wall Street

Insider Buying Stays Solid as Market Races Toward Record Highs

The stock market continues to act like an aging prize-fighter, one that will not give up despite all the haymakers landed. With conflicting economic data, rising job layoffs from the ...
Read Full Story »
Biotechnology word cloud

Short Sellers Look Scared of Big Biotech

The short interest data are out for the January 30 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
downgrade

Credit Suisse Gives Up on Gilead, Sort Of

Gilead Sciences Inc. (NASDAQ: GILD) recently reported earnings and they were, generally speaking, favorable. Consensus estimates were beat on both the top and bottom line due to a strong sales ...
Read Full Story »
road fork sign

Top Analyst Upgrades and Downgrades: Best Buy, Gilead, KeyCorp, NBG, Pandora, Staples, Yelp and More

Stocks were looking for direction on an unemployment Friday before and even after a strong payrolls number. The major rally seen this week, on the heels of a bad January, only ...
Read Full Story »
Stock Split Image

Gilead Dividend and Buyback Different From Amgen’s Strategy

Most investors invest in biotech companies for their drug pipelines and endless growth potential. The problem is that eventually biotech companies can get so large that they are effectively just ...
Read Full Story »
Pills

Will Increased Competition Hurt Gilead’s Outlook?

Gilead Sciences Inc. (NASDAQ: GILD) reported its fourth-quarter results Tuesday after the markets closed as $2.43 in earnings per share (EPS) and $7.3 billion in revenue, against Thomson Reuters consensus ...
Read Full Story »
biotech

What to Expect From Gilead Earnings

Tuesday after the markets close, Gilead Sciences Inc. (NASDAQ: GILD) will report its fourth-quarter financial results. Thomson Reuters has consensus estimates of $2.22 in earnings per share (EPS) and $6.72 ...
Read Full Story »
payoff

The Top 10 Corporate Earnings for the Week Ahead

Corporate earnings season is just reaching its peak, and 24/7 Wall St. has put together a preview of some of the larger companies reporting in the coming week. We have taken ...
Read Full Story »
Biotechnology word cloud

Short Sellers Starting to Gang Up on Biotech

The short interest data are out for the January 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »
merck

Merck Is Top DJIA Stock in 2015

Among the 30 stocks that comprise the Dow Jones Industrial Average (DJIA), Merck & Co. Inc. (NYSE: MRK) was among the top performers in 2014, up about 14%, nearly double ...
Read Full Story »
Biotechnology word cloud

Short Interest in Biotechs Signals Optimism

The short interest data are out for the December 31 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can ...
Read Full Story »